TU-G-BRC-05: Daily Respiratory Gating Window Adjustment Is Necessary for Abdominal Radiation Therapy Patients: A Retrospective Analysis with Simulation 4DCT and Daily Fluoroscopy

2011 ◽  
Vol 38 (6Part30) ◽  
pp. 3781-3782
Author(s):  
J Ge ◽  
L Santanam ◽  
C Noel ◽  
P Parikh
Keyword(s):  
Radiation Therapy ◽  
Retrospective Analysis ◽  
Respiratory Gating ◽  
Gating Window

SU-GG-T-378: Development of Error Analysis Program for Phase-Based Respiratory Gating Radiation Therapy

2008 ◽  
Vol 35 (6Part15) ◽  
pp. 2812-2812
Author(s):  
J Song ◽  
M Yoon ◽  
T Nam ◽  
S Ahn ◽  
W Chung ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Error Analysis ◽  
Respiratory Gating ◽  
Analysis Program

scholarly journals Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study

2019 ◽  
Vol 138 ◽  
pp. 114-120 ◽  
Author(s):  
Yvonne M. Mowery ◽  
Kirtesh Patel ◽  
Mudit Chowdhary ◽  
Christel N. Rushing ◽  
Kingshuk Roy Choudhury ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Retrospective Analysis ◽  
Advanced Melanoma ◽  
Safety And Efficacy

scholarly journals Factors Associated with and Temporal Trends in the Use of Radiation Therapy for the Treatment of Pituitary Adenoma in the National Cancer Database

2019 ◽  
Author(s):  
Ramie Fathy ◽  
Edward Kuan ◽  
John Y. K. Lee ◽  
M Sean Grady ◽  
Michelle Alonso-Basanta ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pituitary Adenoma ◽  
Retrospective Analysis ◽  
Pituitary Adenomas ◽  
Temporal Trends ◽  
Benign Tumors ◽  
National Cancer Database ◽  
Cancer Program ◽  
To Receive ◽  
Over Time

Abstract Purpose Radiation therapy represents an uncommon but important component of treatment plans for some pituitary adenomas (PAs). Although radiation therapy has been used to treat pituitary adenomas for over a century, general trends in the usage of radiation therapy for this purpose have not been reviewed. Additionally, there are few large studies evaluating how radiation therapy is used for the treatment of these benign tumors. Investigating these trends and identifying any variations in radiation therapy utilization would help to better inform treatment decisions and improve patient outcomes. Design Present study is a retrospective analysis of cases using the National Cancer Database. Setting The research was organized at a tertiary academic medical center. Participants Patients were diagnosed with pituitary adenoma between 2004 and 2014 within the National Cancer Database (NCDB). Methods Temporal trends in the usage of radiation therapy to treat pituitary adenoma were analyzed through a retrospective analysis of 77,142 pituitary adenoma cases from the NCDB between 2004 and 2014. Univariate and multivariate analyses were to examine the relationship between patient, tumor, and treatment factors, and the incorporation of radiation therapy into the treatment of pituitary adenomas. We adjusted for potential confounders such as age, sex, race, comorbidity score, facility type, and year of diagnosis. Results A total of 77,142 patients met inclusion criteria. Inclusion of radiation therapy in pituitary adenoma treatment was 8.0% in 2004 and steadily declined to a low of 3.1% in 2014. Overall, patients were less likely to receive radiation for their pituitary adenoma over time (p < 0.001). Similarly, patients were found to be less likely to receive any type of treatment for PA over time (p < 0.001). Multivariable evaluation found patients who were female, between 54 and 64 years of age, or treated at either a Comprehensive Community Cancer Program or an Integrated Network Cancer Program were more likely to receive radiation as part of their pituitary adenoma treatment (p < 0.001, odds ratio [OR] = 2.01, confidence interval [CI]: 1.54–2.63; p < 0.001, OR = 1.84, CI: 1.38–2.44, respectively). Patients were less likely to receive radiation for their PA if they were African American (p < 0.001, OR = 0.81, CI: 0.72–0.91). Logistic regression also identified a progressive increase in the likelihood of receiving radiation after a PA diagnosis with increasing tumor size starting with microscopic tumors, peaking at 4 to 5 cm (p < 0.001; OR = 15.57; CI: 12.20–19.87). Conclusion In this sample of pituitary adenoma patients treated at NCDB institutions between 2004 and 2014, we found a steady decline in the incorporation of radiation therapy in treatment, as well as in the use of any type of intervention for PA treatment, suggesting a rise in noninterventional observation of PA.

scholarly journals Stereotactic body radiation therapy (SBRT) and respiratory gating in lung cancer: dosimetric and radiobiological considerations

2010 ◽  
Vol 11 (1) ◽  
pp. 158-169 ◽  
Author(s):  
Tania De La Fuente Herman ◽  
Maria T. Vlachaki ◽  
Terence S. Herman ◽  
Kerry Hibbitts ◽  
Julie A. Stoner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Respiratory Gating ◽  
Stereotactic Body Radiation

scholarly journals Respiratory gating based on internal electromagnetic motion monitoring during stereotactic liver radiation therapy: First results

2015 ◽  
Vol 54 (9) ◽  
pp. 1445-1452 ◽  
Author(s):  
Per Rugaard Poulsen ◽  
Esben Schjødt Worm ◽  
Rune Hansen ◽  
Lars Peter Larsen ◽  
Cai Grau ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Respiratory Gating ◽  
First Results

Short Cycle of Immunochemotherapy Followed by Radiation Therapy Compared with Prolonged Cycles of Immunochemotherapy for Localized DLBCL: The Osaka Lymphoma Study Group (OLSG) Retrospective Analysis

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1628-1628 ◽  
Author(s):  
Yoshiki Terada ◽  
Hironori Take ◽  
Hirohiko Shibayama ◽  
Koji Hashimoto ◽  
Maki Kuwayama ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Retrospective Analysis ◽  
Treatment Option ◽  
Conflicts Of Interest ◽  
Treatment Options ◽  
B Cell Lymphoma ◽  
Study Group ◽  
Short Cycle ◽  
Treatment Groups ◽  
Lymphoma Study Group

Abstract Abstract 1628 Introduction: Standard treatment for localized diffuse large B cell lymphoma (DLBCL) has been rather a short cycle of immunochemotherapy followed by involved field radiotherapy or prolonged cycles of immunochemotherapy. There is no convincing evidence in favor of either strategy. This retrospective analysis is an attempt to compare these treatment options. Methods: Patients were eligible if they had histologicaly newly diagnosed localized DLBCL by the Osaka Lymphoma Study Group (OLSG) central review panel and registered between 2003 and 2011, and received rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) like immunochemotherapy with more than three consecutive courses as initial therapy. In this study, we defined a localized DLBCL as DLBCL with Ann Arbor stage I or non-bulky (<10cm) stage II. One hundred thirty-seven localized DLBCL patients were analyzed retrospectively. Of 137 patients, 83 had 6 to 8 cycles of R-CHOP like immunochemotherapy (Chemo group), and 28 had 3 to 4 cycles of R-CHOP like immunochemotherapy followed by radiotherapy (Chemo+RT group). In this study, the efficacy and tolerability of the 2 treatment groups, Chemo group and Chemo+RT group, in localized DLBCL patients were compared. Treatment outcomes were evaluated, overall survival (OS), progression free survival (PFS) and toxicity were compared according to each treatment option and risk factor. Results: With a median follow-up time of 34 months, neither OS nor PFS differ between these treatment groups. The 3-year OS were 85.5% in Chemo group and 96.2% in Chemo+RT group, respectively (P=0.225). The 3-year PFS were 74.3% in Chemo group and 89.7% in Chemo+RT group, respectively (P=0.185). A multivariate Cox regression model showed that Chemo+RT group have a tendency to improve PFS [hazard ratio =0.33; 95% confidence interval 0.10–1.07; P =0.066] of localized DLBCL compared with Chemo group. Grade 3 to 4 neutropenia and neutopenic fever were more frequent in patients with Chemo group (P<0.01, P<0.01, respectively). Conclusion: For the treatment of localized DLBCL, although the difference between two treatment options was not significant in efficacy, short cycle of immunochemotherapy followed by radiation therapy seems to be superior to prolonged cycles of immunochemotherapy in terms of safety. Further studies are needed to define the optimal treatment option for localized DLBCL in the rituximab era. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document